Characterisation of lipoproteins from patients with preeclampsia compared to healthy, pregnant and healthy, non-pregnant women

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005368

Enrollment

350

Registered

2013-11-05

Start date

2014-02-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia O14

Interventions

Group 1: Pregnant women with diagnosed preeclampsia: An additional volume of approximately 25 mL blood will be sampled once in the context of routine diagnostic measurements. Plasmalipids will be subj

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Group 1 (case): Pregnant women with preeclampsia according to the criteria of the German Society of Gynaecology and Obstetrics: hyptertension in pregancy (RR>140/90mmHg) and proteinuria (>300 mg/24h) occuring after the 20th week of pregnancy. Preeclampsia can also be diagnosed without proteinuria if fetal growth restriction, liver involvement, renal insufficiency, neurological dysfunctions or hematological disorders are observed after the 20th week of pregnancy. Informed consent. Age >18 years. Group 2 (control): for every individual from group 1 a healthy, pregnant women in matching gestational age (+/- 1 week). Informed consent. Age > 18 years. Group 3 (control): Healthy, non pregnant women. Informed consent. Age > 18 years and < 45 years.

Exclusion criteria

Exclusion criteria: Group 1 (case): lack of informed consent. Group 2 and 3 (controls): lack of informed consent. By anamnesis detection of: arterial hypertension, treatment with antihypertensive agents and other cardiac drugs, diabetes mellitus, renal insufficiency, lipid disorders, liver diseases.

Design outcomes

Primary

Measure	Time frame
Comparison of lipidvalues from ultracentrifugation process and subsequent enzymatic measurement. Exploratory analysis of results, therefore no further specification of endpoints possible.	—

Secondary

Measure	Time frame
Comparison of the influence of different lipoproteinfraction obtained from ultracentrifugation process on vasoactive receptors and their second messengers in cell culture models. Exploratory analysis of results, therefore no further specification of endpoints possible.	—

Countries

Germany

Contacts

Public ContactChristine Contini

Universitätsklinikum Freiburg Institut für Klinische Chemie und Laboratoriumsmedizin

christine.contini@uniklinik-freiburg.de+49 761 270-35320

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026